Earlier this week, Travere Therapeutics reported Q2 2026 results showing revenue rising to US$169.58 million from US$114.45 ...

Travere Therapeutics (TVTX) drew investor attention on 4 August 2026 after reporting second quarter results that combined ...

Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand ...

Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation ...

(Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conf ...

Travere Therapeutics Inc. stock grades by Barron's. View TVTX fundamental and sentiment analysis powered by MarketGrader.

(SHOP) was up 25.3% in pre-market trading, and Travere Therapeutics Inc. (TVTX) was up 12.7%.

3 Under-the-Radar Healthcare Companies Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record ...

Q2 reframed FILSPARI as a two-indication commercial story, with management emphasizing it was "the first quarter with FILSPARI commercially available across both IgA nephropathy and FSGS" (President, ...

Travere Therapeutics, Inc. ( TVTX) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDT Good morning, and welcome to Travere Therapeutics Second Quarter 2026 Financial Results Conference Call. Today's ...